Gestational diabetes, high blood sugar that develops during pregnancy, is common and, for the most part, prevented and managed with diet, activity, and medical care. So the idea that a simple supplement might lower the odds of getting it is understandably appealing. A large 2026 analysis put myo-inositol, a compound already used for blood sugar in polycystic ovary syndrome, to that test. The result is a real and repeated signal, wrapped in some genuinely important limits. This post covers what the study found, how strong the evidence actually is, how myo-inositol works, who it might be for, and the safety context that matters most in pregnancy.
The benefit, in plain terms
Here is the short version. Myo-inositol is a supplement, related to a sugar your body already makes, that has been used mainly to help blood sugar in PCOS. Pooling the pregnancy trials, women who took it were noticeably less likely to be diagnosed with gestational diabetes, about 44% less likely. That sounds big, and it is a real, repeated signal. But two honest points keep it in perspective: the studies did not show it actually improved birth outcomes like the baby's size or preterm birth, and no major medical guideline currently recommends it, because the evidence is still limited. So this is a promising option to raise with your OB or midwife, especially if you are at higher risk of gestational diabetes, not something to start on your own.
The new study, in one paragraph
A 2026 systematic review and meta-analysis in the American Journal of Obstetrics and Gynecology pooled 12 randomized controlled trials covering 4,765 women without preexisting diabetes, taking myo-inositol during pregnancy or before conception. Myo-inositol was associated with a 44% lower risk of being diagnosed with gestational diabetes compared with control. Importantly, the pooled analysis found no significant difference in the outcomes that matter most for mother and baby, including a large baby (macrosomia), preterm birth, newborn low blood sugar, cesarean delivery, and high-blood-pressure disorders of pregnancy. Most included trials were moderate to high quality, with some risk-of-bias concerns.
American Journal of Obstetrics and Gynecology, 2026 (online ahead of print). Meta-analysis, 12 RCTs, 4,765 women. PMID 42242341.
The short version
- A 2026 meta-analysis of 12 trials (4,765 women) linked myo-inositol to a 44% lower risk of being diagnosed with gestational diabetes.
- The signal is real and replicated: a 2023 Cochrane review found nearly the same, and a landmark 2015 trial in higher-risk women found even more.
- The key caveat: it lowered the diagnosis, but did not significantly improve hard outcomes like the baby's size, preterm birth, or newborn blood sugar.
- The evidence is rated low certainty, and no major guideline recommends it. It is promising but investigational, not standard care.
- Trials used about 4 grams of myo-inositol a day (2 grams twice daily) with folic acid, from early pregnancy. Treat it as an OB conversation, not a self-start.
What the study found
The review gathered 12 randomized trials, covering 4,765 women without preexisting diabetes, that gave myo-inositol or a control during pregnancy or the preconception window, then tracked who went on to develop gestational diabetes. Pooled together, the women taking myo-inositol were about 44% less likely to be diagnosed with it. On its own, that is a striking number for a supplement.
But the most honest and most important part of the study is what did not change. Gestational diabetes matters because of what it can lead to: a larger baby, a higher chance of a cesarean, preterm birth, newborn low blood sugar, and high-blood-pressure problems in pregnancy. In this analysis, myo-inositol did not significantly improve any of those. In other words, it lowered the number of women who crossed the line into a gestational-diabetes diagnosis, but it did not clearly change the downstream outcomes that the diagnosis is meant to protect against. That gap is the single most important thing to understand here, and it is why even a big-sounding 44% has to be read carefully.
How strong is the evidence
The reassuring part is that this is not a lone result. The direction and rough size have shown up before:
| Study | What it found |
|---|---|
| 2026 AJOG meta-analysis (12 trials, 4,765 women) | About 44% lower risk of a gestational-diabetes diagnosis |
| 2023 Cochrane review (7 trials, 1,319 women) | About 47% lower risk (RR 0.53), but rated low certainty |
| 2015 landmark trial (220 higher-risk women) | Gestational diabetes in 14% vs 34% on control |
Three analyses landing in the same place is a genuine point in myo-inositol's favor. But the caveats are just as real. The influential Cochrane reviewers explicitly rated the evidence as low certainty and said they could not yet recommend it. Many of the trials are small, and a large share come from a single research group in Italy, which raises questions about how well the results generalize to other populations. The 2026 review itself flagged some risk-of-bias concerns. Put simply, the effect looks real, but the quality of the evidence behind it is not yet strong enough for the medical field to act on with confidence.
How myo-inositol works
Myo-inositol is a naturally occurring compound, found in foods like beans, grains, and fruit and also made by your own body, that plays a role in the way cells respond to insulin. When insulin tells a cell to take in glucose, part of that signal is carried by messengers made from myo-inositol. Supplying more of it may help those signals work more smoothly, so tissues respond to insulin a little better and blood sugar runs lower. This is the same reasoning behind its use in PCOS, where insulin resistance is central. Because gestational diabetes is largely driven by the insulin resistance that naturally rises in pregnancy, myo-inositol was a logical candidate to test. It is a plausible, evidence-supported mechanism, though not a fully proven one in pregnancy.
Who it might be for
The honest answer is: this is a conversation to have with your obstetric provider, not a decision to make from a blog post. To be clear about the current status:
- It is investigational, not standard care. No major body, including ACOG, the ADA, the WHO, or NICE, currently recommends myo-inositol to prevent gestational diabetes. The proven foundations remain a healthy diet, physical activity, and appropriate prenatal care and screening.
- The trials focused on higher-risk women, such as those with obesity, PCOS, or a family history of diabetes. If that describes you, it is a reasonable thing to ask your provider about; if you are low risk, the case is weaker.
- It is not a substitute for anything. It does not replace glucose screening, and if gestational diabetes is diagnosed, it does not replace the treatment your care team prescribes.
How it is used
- The studied approach. Trials generally used about 4 grams of myo-inositol a day, split as 2 grams twice daily, along with folic acid, started in the first trimester or before conception. They used pure myo-inositol.
- Pure myo-inositol versus the 40:1 blend. The popular myo-inositol plus D-chiro-inositol 40:1 blends (sold heavily for PCOS) are well made and precisely dosed, but the extra D-chiro-inositol was not part of the gestational-diabetes trials. Pure myo-inositol is the more study-faithful choice.
- Keep taking your prenatal. Folic acid or folate is essential and is separate from myo-inositol. Most myo-inositol products contain no folate, and your prenatal already provides it, so do not stop your prenatal or rely on inositol for folate.
- Safety in short. In the trials myo-inositol was generally well tolerated, with side effects (mostly mild stomach upset at higher doses) similar to placebo. But the trials are small and short, so long-term safety is not fully mapped, and that is one more reason to involve your provider.
Products worth considering
If your provider agrees myo-inositol makes sense for you, these are reputable options, chosen so you can reach the studied dose from a well-made product. Because this is pregnancy, treat the list as something to review with your OB, not a green light to self-start.
Frequently asked questions
Does myo-inositol prevent gestational diabetes?
A 2026 meta-analysis of 12 trials found women who took myo-inositol were about 44% less likely to be diagnosed with gestational diabetes, and earlier reviews found similar. So the research points to a real reduction in the diagnosis. But the same analysis did not show improvements in outcomes like the baby's size or preterm birth, the evidence is rated low certainty, and no major guideline recommends it yet. It is promising but not proven prevention, and not standard care.
How much myo-inositol, and which type, was used in the studies?
The trials generally used about 4 grams of myo-inositol a day, taken as 2 grams twice daily, usually with folic acid, started in early pregnancy or before conception. They used pure myo-inositol. The popular myo-inositol plus D-chiro-inositol 40:1 blends sold for PCOS were not what the gestational-diabetes trials tested.
Is myo-inositol safe in pregnancy?
In the trials, myo-inositol was generally well tolerated, with no serious problems reported and side effects (mostly mild stomach upset at higher doses) similar to placebo. That said, the trials are relatively small and short, so long-term safety is not fully characterized, and being well tolerated in studies is not the same as an official recommendation for routine use. Any supplement in pregnancy should be cleared with your obstetric provider first.
Should I take myo-inositol if I am pregnant or trying to conceive?
That is a decision for your OB or midwife, not something to start on your own. It is not part of standard prenatal care, and guidelines do not recommend it for preventing gestational diabetes. If you are at higher risk, for example obesity, PCOS, or a family history of diabetes, it is a reasonable thing to ask your provider about, alongside the proven basics of a healthy diet and activity.
Myo-inositol or the myo plus D-chiro 40:1 blend?
The gestational-diabetes trials used pure myo-inositol, so that is the most study-faithful choice. The 40:1 myo plus D-chiro-inositol blends are the standard in PCOS and are well made and precisely dosed, but the extra D-chiro-inositol was not part of the pregnancy studies. Either way, discuss it with your provider.
Do I still need folic acid and a prenatal vitamin?
Yes. Folic acid or folate is essential in pregnancy and is separate from myo-inositol; the trials gave both. Most myo-inositol products do not contain folic acid, and your prenatal vitamin already provides it, so keep taking your prenatal and do not rely on a myo-inositol supplement for folate.
The bottom line
Myo-inositol is one of the more promising supplements in the pregnancy space, and the 2026 review shows why: across 12 trials it was linked to a 44% lower chance of a gestational-diabetes diagnosis, a result that earlier analyses have echoed. Read honestly, though, the picture is more measured. It lowered the diagnosis but did not clearly improve the birth outcomes that diagnosis is meant to prevent, the evidence is rated low certainty, and no medical guideline endorses it yet. That makes myo-inositol a reasonable option to discuss with your obstetric provider, particularly if you are at higher risk of gestational diabetes, and never a replacement for prenatal screening, a healthy lifestyle, or the care your team recommends. If you and your provider decide to try it, the studied approach is pure myo-inositol at about 4 grams a day, alongside the prenatal and folate you are already taking.